Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
Completed
- Conditions
- Asthma
- Registration Number
- NCT00784953
- Lead Sponsor
- AstraZeneca
- Brief Summary
A non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to Symbicort SMART or various identical regimens.
The study will be implemented by screening asthmatic patients from respiratory clinics to identify those not optimally controlled and required stepping up the controllers to initiate, or to titrate dose of, ICS/LABA including Symbicort.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 842
Inclusion Criteria
- Asthma patient who was partly controlled or uncontrolled by previous controllers of ICS only, or low dose ICS plus either LABA, leukotriene modifier or theophylline; or ICS- naïve with severe and persist symptom based on physician's judgment
- According to GINA guideline, who need to step up the controller medications, and ICS/LABA to be prescribed based on physician's discretion
Exclusion Criteria
- Patients aged not within limitation refer to label information of various product prescribed
- Patients who have taken oral corticosteroids within 4 weeks prior to enrollment
- Patients with contraindications to prescribed medication
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in ACQ score from baseline to the mean of all available data from the follow up visits wk 4±1; wk 12~16
- Secondary Outcome Measures
Name Time Method Change in the individual asthma control status & pulmonary function from enrollment wk 4±1; wk 12~16 Dose/usage of ICS/LABA and relievers & Patient compliance wk 4±1; wk 12~16 Medical resource utilization wk 4±1; wk 12~16; 6 month; 12 month
Trial Locations
- Locations (1)
Research Site
🇨🇳Taipei, Taiwan